Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies
These results illustrate that the K<sub>m</sub> for [<sup>14</sup>C]UA uptake was not altered in the presence of <b>2</b> or <b>3</b>, but rather the V<sub>max</sub> was reduced in the presence of inhibitors when added to the uptake solutions. As a result, these data support the notion that <b>2</b> and <b>3</b> inhibit [<sup>14</sup>C]UA uptake by non-competitive inhibition and not at the URAT1 binding site.
Authors
- Janet Lightner
- Vijay Kumar (ORCID: https://orcid.org/0000-0002-8035-9181)
- Michael F. Wempe (ORCID: https://orcid.org/0000-0002-8157-5281)
- Peter J. Rice
- Naohiko Anzai (ORCID: https://orcid.org/0000-0003-0605-0458)
- Promsuk Jutabha (ORCID: https://orcid.org/0000-0002-8475-8921)
- Hitoshi Endou
Institutions
- East Tennessee State University (US)
- Chiba University (JP)
- Kyorin University (JP)
- Mahidol University (TH)
- University of Colorado Cancer Center (US)
- Ramathibodi Hospital (TH)
- University of Colorado Anschutz Medical Campus (US)
- Dokkyo Medical University (JP)
- Kentucky State University (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/dddt.s474398
- Citations
- 3
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 4.29
Funders
- East Tennessee State University
- Japan Society for the Promotion of Science